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Introduction
Gallbladder cancer (GBC) is a common disease in South 
America (1). It is possible that risk factors, molecular 
abnormalities and clinical behavior are different in 
comparison to GBC diagnosed in other regions. We present 
an overview of the situation of this disease in the area where 
we reside. Clinical characteristics, risk factors, genetic 
abnormalities and treatment approaches are described in 
order to picture the magnitude of this problem.
Epidemiology
Biliary tract cancers (BTC) include GBC, intrahepatic-
cholangiocarcinoma (CC), extrahepatic-cholangiocarcinoma 
(EHCC) and some forms of ampullary cancer. Among them, 
GBC is the most prevalent cancer type in South America. 
Its incidence and mortality rates vary among areas; even 
within the same country remarkable differences in terms of 
mortality rates have been observed (1,2). Cancer registries 
are not well developed in some countries of South America, 
and in these cases mortality rates constitute an alternative 
to indirectly obtain information about the magnitude 
of this health problem. Furthermore, utilizing this 
approach is reliable because GBC is a highly lethal disease; 
therefore mortality rates can equalize incidence. This 
notwithstanding, caution is warranted because mortality 
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rates due to GBC may be underestimated as well. In fact, 
in many South American countries the death certificates, 
which are the source for obtaining mortality rates, do not 
show that cancer (any type) was the cause of death. An 
example of such situation is reflected by the data on age-
standardized mortality rates (ASMR) from Argentina vs. 
USA. In the former the ASMR due to cancer in general was 
88 and 131/105/year for women and men, respectively (2). 
While in the later the ASMR were 145 and 208/105/year 
for women and men, respectively (3). This big difference in 
terms of ASMR can be explained, at least in part, by sub-
registration of death from cancer. 
Hepatobiliary tumors fall into two categories of the 
International Agency for Research on Cancer (IARC) 
report. Intrahepatic-CC and liver cancer are included in 
the ICD-10 C22 category, whereas GBC and EHCC in 
the ICD-10 C23-24. Intriguingly, ampullary cancer still 
remains unclassified in this report. In South America, the 
ASMR for tumors included within the category ICD-10 
C22 are similar or below to that reported for other parts of 
the world (1). On the contrary, the geographic distribution 
of ASMR data for tumors belonging to the ICD-10 C23-24 
category, in which GBC accounts for the majority of deaths, 
is substantially different. Furthermore, important variations 
in terms of ASMR in women have been found among South 
American countries (Table 1).
In Chile, and according to official statistics (4), a total 
of 23,716 deaths caused by GBC and EHCC have been 
reported for the period 2000–2012; among them 72.3% 
were women. Median ASMR was 15.04/105 women/year 
[interquartile range (IQR) 4.56)]. The highest ASMR were 
registered in the southern regions of Los Ríos (24.26; 
IQR 5.64), Los Lagos (23.69; IQR 4.14) and Aysén (18.29; 
IQR 7.78); while the lowest ASMR were described in the 
metropolitan region of Santiago de Chile (11.40; IQR 3.52) 
at the center, and Tarapacá at the north of the country 
(11.42; IQR 8.37). GBC and EHCC were the second 
leading cause of death from cancer in women in the whole 
country. On the other hand, the median ASMR for Chilean 
men was 5.52 (IQR 1.73), and the region of Aysen showed 
the highest ASMR (8.83; IQR 6.91).
In Brazil (5), GBC and EHCC accounted for 16,808 
deaths in the period 2007–2012, and the majority 
corresponded to women (66.8%). The median national 
ASMR was 1.79/105 women/year (IQR 0.19). The highest 
ASMR were registered in the southern region of Rio 
Grande do Sul (2.08; IQR 0.16). Despite of this GBC and 
EHCC do not fall within the ten most common type of 
cancer causing deaths in every regions of the country, in 
both genders.
In Uruguay (6), at the southeast of South America, there 
were 1,058 deaths due to GBC and EHCC during the 
period 2006–2010, and 63.1% of them were women. The 
national ASMR for that period was 4.1/105 women/year.
Peru and Ecuador located at the central-western area 
of SA are two countries in which incidence rates are 
available. Age-standardized incidence rates (ASIR) were 
7.5/105 women/year in Trujillo (Peru) and 7.4 in Quito 
(Ecuador) (7).
In Argentina, GBC and EHCC accounted for 5,262 
(1.5%) of all cancer deaths in the period 2007–2011 (2). Out 
of them 3,806 (72.3%) occurred in women. The country 
overall ASMR was 2.5/105 women/year [95% confidence 
interval (CI), 2.4–2.5)] and 2.1/105 men/year (95% CI, 
2.0–2.1). GBC and EHCC are among the ten most frequent 
(8th) cause of death from cancer in women, but not for men. 
Table 1 GBC and extrahepatic cholangiocarcinoma ASMR and ASIR among women in South American countries§
Country Region Geographic location in South America ASMR (×105 women/year) ASIR (×105 women/year)
Argentina Jujuy West 8.9 —
Argentina Misiones East 1.5 —
Brazil Country East 1.7 —
Uruguay Country East 4.1 —
Peru Trujillo West — 7.5
Ecuador Quito West — 7.4
§, incidence rates equalize mortality rates; the majority of cases correspond to gallbladder cancer; ASMR, age-standardized mortality 
rates; ASIR, age-standardized incidence rates; GBC, gallbladder cancer.
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The territory of Argentina can be divided in five geographic 
regions (Figure 1) which exhibit particular ethnical, political, 
historical, socio-economical characteristics, as well as 
differences in term of access to health care (8). Interestingly, 
the ASMR because GBC and EHCC varies between these 
regions (Table 2, Figure 2). The highest ASMR have been 
determined for the Northwest (NW) and the Patagonia 
regions, while the lowest values were estimated for the 
Northeast (NE) and Pampeana regions on the east side of 
the country.
In the NW region, Jujuy showed an ASMR for women 
of 8.9 (95% CI, 7.4–10.3). Similarly, in the province of Salta 
the ASMR for women was 7.0 (95% CI, 6.0–8.0), occupying 
the third place among the leading causes of death from 
cancer in women in both provinces. In the province of La 
Rioja ASMR for women was 4.4 (95% CI, 3.1–6.0) being 
the fifth leading cause of cancer death in women.
In the province of Neuquén (Patagonia region) the 
ASMR for GBC and EHCC was 4.6 (95% CI, 3.5–5.8), 
placing these tumor types at the 8th leading cause of cancer 
death in women. In Rio Negro, belonging to the same 
region, women ASMR was 4.1 (95% CI, 3.2–5.1), reaching 
the 7th place in the leading causes of death from cancer in 
women.
The lowest ASMRs for GBC and EHCC in women 
(1.4) were registered in the provinces of Entre Rios and 
Buenos Aires, and the Autonomous City of Buenos Aires 
itself (CABA), all of which belong to the eastern Pampeana 
region.
In summary, the data about mortality rates due to GBC 
indicate that the incidence of this tumor type in South 
America is distinct in different geographic areas. While 
in the eastern countries, like Uruguay and Brazil and 
the NE region of Argentina the data on ASMR due to 
GBC are similar to those of the United States of America 
and Western Europe (9), in Chile and western areas of 
Argentina the same measurements yielded higher values. In 
western countries such as Peru and Ecuador ASIR (which 
equalizes ASMR) were high. These data suggest that there 
is a widely extended territory near the Andes Mountains in 
which people are at high risk of developing GBC. 
Etiology and risk factors for GBC in South 
America
The pathogenesis of GBC is not completely elucidated; 
however it is known that genetics and environmental 
factors play important roles in the initiation, promotion and 
progression of the disease (Table 3). 
Non-manageable risk factors
GBC mortality increases with aging. In Argentina, in the 
period 2007–2011 the number of deaths in women was 
70, 340, 456 and 547 in the 40–44, 55–59, 64–69 and 75– 
79 year groups respectively; in men deaths due to GBC were 
31, 232, 367 and 415 in the same age groups, respectively (2). 
In the USA, in the period 2008–2012, a similar distribution 
of deaths due to GBC has been observed in both sexes (3). 
We could speculate that this epidemiological characteristic 
responds to the accumulation of hits which are required by 
the process of carcinogenesis. 
As mentioned before this tumor type is more prevalent 
among women, and it has been proposed a link between 
this feature and the estrogen levels. Females having early 
menarche, late menopause, multiple pregnancies and 
childbirths appear to have an increased risk of developing 
GBC according to a case-control study from India (19). 
Interestingly, estrogens increase the formation of gallstones, 
mainly by elevating biliary cholesterol (20). This could 
Figure 1 Regions and territories of Argentina.
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explain, at least partially, why GBC is more prevalent in 
women.
The contribution of the genetic background as predisposing 
factor for GBC emerges from the analysis of migratory 
phenomenon from high incidence areas in Chile and 
Bolivia to Argentina. The NW region in Argentina shares 
Table 2 Women ASMR from gallbladder cancer and extrahepatic cholangiocarcinoma in Argentina during the period 2007–2011
Territory Cases ASMR (×105 women/year) 95% CI Regional median ASMR
NW
Jujuy 161 8.9 7.4–10.3 4.4
Salta 206 7.0 6.0–8.0
Catamarca 41 2.8 2.4–4.7
La Rioja 41 4.4 3.1–6.0
Tucumán 169 3.8 3.2– 4.4
Santiago del Estero 86 3.9 3.1–4.8
Cuyo
San Juan 90 4.0 3.2–5.0 4
San Luis 52 4.0 3.0–5.3
Mendoza 184 2.8 2.4–3.3
Patagonia
Neuquén 65 4.6 3.5–5.8 3.8
Río Negro 75 4.1 3.2–5.1
Chubut 45 3.4 2.4–4.6
Santa Cruz 19 3.6 2.1–5.7
Tierra del Fuego 9 4.0 1.8–7.7
Pampeana
Buenos Aires 1,258 1.4 1.9–2.1 1.6
CABA 303 1.4 1.2–1.6
La Pampa 26 1.8 1.1–2.7
Córdoba 390 2.7 2.4–3.0
Santa Fe 278 1.9 2.1–5.7
Entre Ríos 78 1.4 1.1–1.8
NE
Corrientes 73 2.5 1.9–2.5 2.3
Chaco 85 3.2 2.5–4.0
Misiones 38 1.5 1.1–2.1
Formosa 26 2.1 1.3–3.0
Country total 3,798 2.5 2.4–2.5 2.5
ASMR, age-standardized mortality rates; CI, confidence interval; CABA, Autonomous City of Buenos Aires; GBC, gallbladder cancer; NW, 
Northwest; NE, Northeast.
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borders with the Chilean region of Antofagasta, and GBC 
mortality rates are similar. The original natives belonged 
to the Omaguacas, Atacamas and Diaguitas tribes, who 
have particular cultural, social, dietary habits and obviously 
specific genomic characteristics. Some of them changed 
dramatically after the Spanish conquest, but resilience 
processes in valleys, however, could preserve them to 
certain extent. Furthermore, this ethnic reality has been 
maintained until today by permanent migrations from 
Bolivia to Argentina, to the point that today about 350,000 
Bolivians and their natural descendants (Argentinean) live 
in Argentina, mostly in Jujuy, Salta and Buenos Aires (21). 
Similar situation is observed in Patagonia, another high 
incidence region in Argentina, where the ancestral 
Pewenches were invaded by Mapuches, coming from the 
south of Chile, establishing a bidirectional population 
flow that persists nowadays (22). Therefore, and given the 
historic and demographic evidences connecting populations 
at both sides of the Andes, it is tempting to speculate that 
genetic background common to those persons predispose 
them to GBC development.  Of course,  thorough 
investigations are needed to verify this hypothesis, but a 
recent study on the genetic variants of the Arsenic+++ Methyl 
Transferase gene (AS3MT) provided the first evidence of 
human adaptation to a toxic chemical (23). It is well known 
that chronic arsenic poisoning may lead to skin cancer, and 
this study revealed that there are, among the population 
residing in the Andean area of Province of Salta, women 
carrying certain haplotype of the AS3MT gene, involved 
in arsenic metabolism, that protect them from the toxic 
effects of arsenic. Additional evidence for the notion that 
genetic factors may contribute to GBC development 
comes from a case-control study in a Chilean population 
about lipid metabolism-related genes. In fact, the rs693 
polymorphism of the Apolipoprotein B gene and the 
rs708272 polymorphism of the Cholesteryl-Ester-Transfer-
Protein gene were associated with an increased risk of GBC 
(OR 5.04; 95% CI, 1.43–17.8) (10). 
Manageable risk factors
Cholelithiasis which leads to chronic cholecystitis remains 
as the most important risk factor for the disease worldwide. 
Gallstones are present in 45–100% of the cases (24), and 
mucosal changes from cholecystitis, hyperplasia, metaplasia, 
dysplasia, to carcinoma correlate positively with the weight, 
and size of the stones (25). The association between 
gallstone disease and GBC is even stronger if this has a 
longstanding history as shown by Serra et al. in a case-
control study of 228 persons from Chile. They reported 
Table 3 Risk factors for GBC in South America
Non-manageable
Age (2,3)
Female Gender (2,4,7)
Genetic background (10-13)
Manageable
Gallstone disease (14)
Red chili pepper consumption and aflatoxin (14-17)
Very low socioeconomic status (14)
Typhoid disease (11,12,18)
GBC, gallbladder cancer.
Figure 2 Age-standardized mortality rates (ASMR) from 
gallbladder cancer (GBC) and extrahepatic cholangiocarcinoma 
among women (aged 1–77 years) in different regions of Argentina 
during the period 2007–2011.
1.14−1.98
1.99−3.02
3.03−3.67
3.68−4.08
4.09−6.99
7.00−8.90
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that 15% of cancer cases had a history of gallstone disease 
longer than 24 years compared to only 4% among control 
cases (OR 11; 95% CI, 1.4–85.2) (14).
In the case-control study mentioned above Serra et al. 
also found that red chili pepper consumption was associated 
with GBC (together with very low socioeconomic status 
and longstanding gallstone disease). The association resisted 
the statistic challenge by multivariate analysis with ORs of 
3.2 (95% CI, 1.7–5.9). Since this is a retrospective analysis 
it is subjected to biases, including recall bias, a common 
limitation when using food frequency questionnaires. In 
support of that finding other studies reported an association 
of chili pepper consumption with stomach, liver and 
esophageal cancer (26-28). Furthermore, in the search for 
the potential etiological factor related to this dietary habit, 
several investigations have shown elevated concentration 
of aflatoxin in red chili peppers consumed by populations 
having high GBC incidence in the Andean areas of Chile, 
Bolivia and Peru (15,16). Nogueira et al. (17) also analyzed 
this association by performing a case-control study 
including 112 Chilean men and women (not distinguishing 
gender), and they found that patients with GBC had higher 
levels of aflatoxin B1-DNA adducts in peripheral blood than 
healthy control individuals (OR 13.2; 95% CI, 4.3–47.9) 
and control individuals with gallstones (OR 9.4; 95% CI, 
2.8–37.2). In summary, there is evidence to consider red 
chili pepper, a frequently consumed food in some regions 
of South America, as a risk factor for GBC. This, in turn, 
could be mediated by the mutagen aflatoxin, a contaminant 
of red chili pepper. However, due to the limitations of the 
studies outlined before, additional research is required to 
confirm the association of red chili pepper consumption and 
GBC development.
Very low socioeconomic status was found associated to 
GBC in the study by Serra et al. described above (14), with a 
ORs of 6.3 (95% CI, 1.7–23.0) after multivariable analysis. 
It is conceivable that people with very low socioeconomic 
status have less access to the health care system and, 
therefore is more likely to have longstanding gallstone 
disease. 
A study performed in Mexico and Bolivia showed that 
patients diagnosed for typhoid disease had a twelvefold 
higher risk of developing GBC (11) which is in agreement 
with studies carried out in USA and Asia (12,18). 
Other possible risk factors are chronic biliary tract 
infection, diet, elevated body mass index, smoking or 
chewing tobacco and genetic factors (11,13,19,29). 
In summary, age, gender (female) and the genetic 
make-up appear as important non modifiable risk factors 
for GBC, whereas cholelithiasis, typhoid disease, as well 
as consumption of red chili pepper contaminated with 
aflatoxin and very low socioeconomic status emerge as risk 
factors on which we may be able to intervene.
Molecular pathology of GBC
Cast i l lo  e t  a l .  (30)  proposed that  the  mal ignant 
transformation of the gallbladder may occur through 
two alternative pathways (models): the sequential change 
from dysplasia to carcinoma and the adenoma-carcinoma 
model. The first postulates that the gallbladder epithelium 
undergoes metaplasia as an adaptive response to chronic 
irritation and inflammation. In fact, such change is found 
in approximately 50% of the patients with cholecystitis, 
and, eventually, on top of the metaplasia, the dysplasia may 
develop, which progress to carcinoma. The second model 
postulates that GBC originates through the malignant 
transformation of glandular tumors, such as benign 
adenomas. 
Regardless the course of the disease, it is accepted that, 
like in the vast majority of neoplastic processes, genetic 
changes play a pivotal role in the development of GBC (31). 
The most frequent genetic abnormalities in GBC are 
depicted in Table 4. Classical cytogenetic studies performed 
on tumor samples of patients from low endemic areas, more 
than a decade ago, showed that the chromosome profile 
of GBC is complex. The tumors contain multiple clones, 
and the chromosome profile was characterized by gains 
of the chromosome arms 7p, 7q, 8q and 17q, and loses 
of 3p, 9p, 10q, 11p, 17p and 21p. Furthermore, several 
Table 4 Frequent genetic abnormalities in GBC
Chromosomal (31,32)
Gains: 7p, 7q, 8q and 17q
Loses: 3p, 9p, 10q, 11p, 17p and 21p
Structural aberrations: del(3)(p13), i(5)(p10), del(6)(q13), del(9)
(p13), del(16)(q22), del(17)(p11), i(17)(q10), del(19)(p13) and 
i(21)(q10)
Molecular
Oncogenes: K-RAS (33-35)
Tumor suppressor genes:p16 (36), FHIT (37), TP53 
(34,36,38,39) 
GBC, gallbladder cancer.
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recurrent chromosome aberrations were detected, including 
del(3)(p13), i(5)(p10), del(6)(q13), del(9)(p13), del(16)
(q22), del(17)(p11), i(17)(q10), del(19)(p13) and i(21)(q10), 
suggesting that these regions contain genes involved in the 
development of GBC (32). 
Roa et al. (40), performed studies aimed to detect 
genomic imbalances in GBC from Chile, and to find whether 
there is any association with the prognosis of the patients. 
Flow cytometry analysis showed that 24% of the tumors 
(29/120) were aneuploidy. However five years survival was 
not significantly worse among these patients compared to 
those with diploid tumors. Molecular studies has allowed to 
identify, among others, tumor suppressor genes, oncogenes, 
genes involved in DNA repair which play important roles 
in the pathogenesis of GBC. Furthermore, and based on 
the analysis of genetic abnormalities of different lesions 
in patients from Chile, it has been possible to propose 
a sequence of molecular events implicated in GBC 
development (30). Activation of the members of the RAS 
family of genes (H-RAS, N-RAS y K-RAS) is perhaps one 
of the most frequent events in human neoplasia. However 
the data on activating mutation of K-RAS in this tumor 
type are quite variable. For example, Pai et al. (33) reported 
that only two out 29 (7%) analyzed tumors of patients 
from USA exhibited K-RAS codon 12 mutations, while the 
frequency of mutation in tissue samples of patients from 
India and Korea was near to 50% and 20%, respectively 
(36,41). Interestingly, differences in the frequency of K-RAS 
mutation were also detected between patients from the NW 
of Argentina and from Bolivia; despite both populations 
subjected to genetic analysis belonged to the same 
geographic area. The study performed to identify the status 
of K-RAS in GBC patients from Bolivia showed that one 
out of 36 (2.8%) had activating mutations of the gene (34), 
while patients from the NW of Argentina exhibited higher 
frequency of this gene abnormalities. In fact, in a study 
including 58 patients of BTC, with a majority of GBC, 
23 patients (39%) had amplification and 8 (17%) had 
mutation of the K-RAS gene (unpublished data). Even 
more, in 21 invasive GBC samples from Chile RAS 
mutations were found in only 2 (10%) (35). This variation 
among high risk areas suggests that environmental factors 
and the genetic background of the people may be related to 
such differences. 
Tumor suppressor genes FHIT mapping on chromosome 
3p14, p16 on 9p21 and TP53 on 17p13 are among the most 
frequently found altered in GBC, and this is consistent 
with the data about imbalances of their genomic regions. 
Kim et al. (36) have detected deletions of the chromosome 
region 9p21 and methylation of the promoter region of 
the p16 gene in 48% of GBC. This correlated with loss 
of the protein expression in 50% of tumors, determined 
by immuno-histochemistry. Methylation in the promoter 
region of the FHIT and p16 genes has been also examined 
by Roa et al. (37) in GBC samples of patients from Chile. 
Methyl-specific PCR showed that 30% of the tumors 
had abnormal methylation of the promoter region of the 
FHIT gene and 20% of p16 gene promoter, and this was in 
agreement with an altered immune-histochemical pattern of 
their protein product. Considering the number of scientific 
papers available in the literature, TP53 is the tumor 
suppressor gene most thoroughly investigated in this tumor 
type (38). The authors mentioned above demonstrated that 
the percentages of tumors with deletions of the locus (81%) 
and mutations of exons 6–8 (67%) are in agreement with 
the high incidence (66%) of overexpression of the mutated 
protein in tumor cells (36). The TP53 gene status has been 
also the focus of genetic studies performed on samples from 
patients from Chile and Bolivia. Unlike to what happens 
to the K-RAS gene, the status of abnormalities of this 
gene is similar among high risk GBC regions. Mutations 
of TP53 were found in more than 50% of tumor samples 
from Bolivia and Chile. However, differences in the type of 
mutations were found, and despite of the fact that exons 5 
and 8 were affected, only a few mutations occurred in hot-
spot codons (34,39). In another study from Chile, Wistuba 
et al. (35), found that deletion of the TP53 locus was an early 
event present in 58%, 85% and 91% of dysplastic tissue, 
carcinoma in situ and invasive carcinoma, respectively.
We have analyzed the expression of the KIT protein 
in GBC samples from our area (42). Contrary to the data 
obtained from a series of patients from USA (43), which 
showed expression of the protein in the majority of tumors, 
only three out of the 50 tumor samples we subjected to 
standard protein immuno-detection, exhibited positive 
reaction. Interestingly all three positive were poorly 
differentiated or undifferentiated tumors, raising the 
hypothesis that this metabolic pathway could be utilized by 
a subset of aggressive GBC.
Roa et al. (44) analyzed the presence of microsatellite 
instability (MSI) in 59 samples from patients with GBC 
and 22 with chronic cholecystitis from Temuco, a high 
risk area for GBC in Chile, and 6 out of the 59 (10%) 
samples showed high MSI. Interestingly none of chronic 
Arroyo et al. Gallbladder cancer in South America
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cholecystitis cases exhibited MSI, whereas it was present 
in 83% (5/6) of surrounding dysplasia, in 33% (2/6) 
of surrounding intestinal metaplasia, and with equal 
proportion in early and advanced stages GBC samples, 
suggesting the hypothesis that mismatch repair deficiency 
is an early event in gallbladder carcinogenesis. In contrast 
MSI has been rarely found in samples from European GBC 
patients (45). Analysis of MSI as a sign of mismatch repair 
deficiency is even more interesting because this molecular 
abnormality has recently been found to be a predictor 
of impressive responses to anti PD-1 therapy, including 
patients with BTC (46).
The Gastrointestinal Oncology Latin-American 
Intergroup (ILOGI) analyzed the transcriptional level of 
different genes as predictive or prognostic factors in 54 
BTC samples (including GBC, CC and ampullary cancer). 
Among others the mRNA level of FBXW7 a gene that 
encodes an ubiquitin ligase that interacts with oncoproteins, 
correlated with progression free survival (PFS) and overall 
survival (OS) in 19 patients (47). Median PFS was 4.9, 
7.6 and 26.9 months for tumors in the lowest, middle and 
upper tercile of expression level. The corresponding median 
OS were 6.2, 8.8 and not reached. Mutational analysis of 
the FBXW7 gene on 30 samples did not reveal structural 
anomalies (unpublished data). This is in contrast with a 
finding by Akhoondi et al. (48) who reported inactivating 
mutations in 7/20 (35%) non-South-American CCs. It 
would be interesting to expand these analyses to a higher 
number of cases in order to confirm FBXW7 mRNA level 
as a prognostic factor in BTC, and to confirm if FBXW7 
inactivating mutations have different prevalence in CCs 
from South America respect to tumors from other regions. 
Given the much higher incidence of GBC in the 
Western area of South America, our results in tumors from 
this area reinforce the notion that particular environmental 
or genetic factors are leading to specific genetic alterations 
which may result in different molecular pathways.
Clinical experience and clinical trials in South 
America
In South America, as expected, the management of the 
patients with GBC has been also carried out by surgery, 
chemotherapy (CHT), radiotherapy or the combination of 
them. Consequently a number of studies, including clinical 
series as well as clinical trials have been performed aimed to 
gain insights into the different treatment options for GBC 
in South America (Tables 5,6).
Before describing the studies on early stage GBC one 
should keep in mind that the majority of early stage GBC 
cases are diagnosed as an incidental finding after a simple 
laparoscopic cholecystectomy. Under this scenario, it is 
recommended performing an extended cholecystectomy. 
This surgical procedure starts with an initial examination 
of the peritoneal cavity and the retroperitoneal lymph 
nodes. If no tumor is found it continues with a regional 
lymphadenectomy, a wedge resection of the gallbladder 
bed (usually including segments IVb and V of the liver), 
and resection of port sites. Supporting evidence for such 
aggressive approach comes from the facts that in tumors 
staged T2 (invasion without penetration of serosa) lymph 
node spread occurs in 48% of patients (56,57) and for stage 
T3 lesions (perforation of serosa or direct invasion to liver 
and/or one adjacent organ) the spread to lymph nodes 
occurs in 72% of patients (57). 
Manterola et al. (49) treated 40 patients from Chile 
with extended cholecystectomy followed by CHT with 
5-fluorouracil/leucovorin. According to the TNM 
Classification of Malignant Tumors (58), the depth 
of penetration of their tumors wereT1/T2/T3/T4 in 
8/12/12/8 patients, respectively, and the 5 year OS was 
50%. Similarly, Lendoire et al. (50) reported 53% 5 year 
OS among 24 GBC patients from Argentina, including 
1 T1, 12 T2 and 11 T3, who were treated with extended 
cholecystectomy and CHT. A large retrospective study was 
Table 5 Data from surgical series of resectable GBC from South America
Reference Country N T1ǂ (%) Extended cholecystectomy (%) CHT Radiaton therapy OS (%)
Manterola et al. (49) Chile 40 20 100 Yes Not 50
Lendoire et al. (50) Argentina 24 4 100 Yes£ Not 53
González et al. (51) Chile 95 28 52 Yes Yes 42
ǂ, TNM classification system of malignant tumors; £, only for residual disease; CHT, chemotherapy; N, number of patients; OS, overall 
survival; GBC, gallbladder cancer.
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recently presented by González et al. at the 2015 Latin-
American Symposium of Oncologic Gastroenterology 
(SLAGO) in Viña del Mar (Chile) (51). These authors 
analyzed the outcome of 95 patients with GBC, including 
mostly very early stage tumors (27 T1, 34 T2 and 34 T3). 
Among them, only 49 patients (52%) were subjected to 
extended cholecystectomy and the remaining received 
simple cholecystectomy. Adjuvant CHT and 3D radiation 
therapy were utilized. Of the total, 42% of the patients were 
alive after 5 years. However, clear differences in term of OS 
were achieved by patients who received either extended or 
simple cholecystectomy, 55% of those who underwent the 
extended procedure were alive after 5 years, whereas only 
29% of those who received simple cholecystectomy were 
alive after 5 years. Moreover, in this study the performance 
of the patients who underwent extended cholecystectomy 
was also evaluated in relationship with the number of lymph 
nodes examined. Five year OS was 67% for those patients 
who had four or more lymph nodes examined, whereas it 
descended to 47% among patients with less than four lymph 
nodes subjected to histopathology exam. Although the data 
were obtained retrospectively, they show the importance of 
extended cholecystectomy as the best treatment alternative 
for those cases with early stage GBC. Another important 
point that can be deduced from the analysis of the 
surgical series presented here is that adjuvant CHT after 
a complete resection of GBC is indicated in the majority 
of cases in South America. This is in agreement with the 
literature reporting that adjuvant CHT is utilized by 70% 
of the centers worldwide for the treatment of this type of 
cancer (59). However, since this decision is based on low 
level evidence it must be confirmed by the ongoing phase 
3 trials (in Japan, France and the United Kingdom) which 
are testing the hypothesis that surgery and adjuvant CHT 
cure more patients than surgery alone. 
Finally, it is important to mention that reports from the 
United States of America and other countries from Asia 
and Europe showed that the 5 year OS rates varied between 
54–100% for T2, 16–63% for T3, and 8–25% for T4 
disease (60), which are to certain extent comparable with the 
OS data from patients with early stage GBCs from South 
America. Therefore, we can assume that the treatment 
strategies established in our patients are well supported by 
the clinical evidence.
As regard to advanced GBC, several attempts to treat the 
patients with CHT have been performed. Gallardo et al. (52) 
carried out a phase 2 trial with first line gemcitabine in 
26 patients with advanced GBC from Chile, and reported 
that an overall response rate (ORR, the sum of partial 
and complete responses) was obtained in 9/25 (36%) and 
that stable disease was achieved by 6/25 (25%) patients, 
while the median OS was 7 months. More than a decade 
ago, Reyes-Vidal et al. (53) presented at the 2004 ASCO 
Gastrointestinal (GI) Meeting results of a phase 2 trial with 
gemcitabine combined with cisplatin in the first line setting 
in 42 patients with advanced GBC from Chile. ORR was 
achieved by 20 out of the 42 (48%) patients, and median 
survival was 6.5 months. Similar treatment protocol was 
administrated to a group of 8 patients with locally advanced 
and metastatic GBC and CC from Argentina, and response 
was obtained in 5 of them (62%); however data about the 
OS was not reported (54). We have surveyed the clinical 
data from 173 patients with GBC and CC from the NW 
region of Argentina, attended by physicians’ members of the 
ILOGI group. There were clear gender differences between 
the two clinical entities, GBC was more prevalent among 
women and CC was evenly distributed. Furthermore, GBCs 
were almost always detected at earlier stages than CC, 
which could be due to the fact that GBC is diagnosed as an 
incidental finding. More important, 69 patients (54 GBC 
and 15 CC) were assessed for their response to gemcitabine 
or cisplatin-based CHT, and overall response was obtained 
Table 6 Clinical trials and series on advanced BTC from South America
Reference Country Design CHT N (GBC/CC) ORR (%) mOS (months)
Gallardo et al. (52) Chile Prospective phase 2 Gemcitabine 25 (25/0) 36 7.0
Reyes-Vidal et al. (53) Chile Prospective phase 2 Gemcitabine; cisplatin 42 (42/0) 48 6.5
Carraro et al. (54) Argentina Prospective phase 2 Gemcitabine; cisplatin 8 (5/3) 62 NR
Arroyo et al. (55) Argentina Retrospective Various 69 (54/15) 27 8#
NR, not reported; #, only GBC patients; CHT, chemotherapy; N, number of patients; ORR, overall response rate; GBC, gallbladder cancer; 
CC, cholangiocarcinoma; OS, overall survival; BTC, biliary tract cancer.
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in 16 out of 54 (30%) GBC patients and 3 out 15 (20%) 
CC patients. The median OS for the GBC patients was 
8 months (55).
In these three trials and the retrospective series the ORR 
ranged from 27% to 62%. However, and despite the good 
response rates, the OS observed among these patients was 
dismal. Similarly, the OS in advanced GBC patients from 
other regions of the world is poor with no evidence of 
cure in any subgroup of patients (61,62). Therefore, new 
treatment strategies for advanced GBC are required. This 
could be accomplished by the identification of new targets 
and the appropriate therapy. In fact recent analyses in tissue 
samples from GBC in 100 patients found between 1 and 
2 potentially targetable genomic alterations per tumor, 
among them ERBB2, PIK3CA, CDKN2A/B and KRAS 
abnormalities (63,64). 
Since no single test for the early diagnosis has been 
shown to decrease mortality, it is reasonable to think that 
prophylactic simple cholecystectomy in a population at 
high risk for GBC in endemic areas could be beneficial, 
in particular for patients with gallstone disease who live in 
western South America. In fact, and in agreement with this 
notion, the Ministry of Health of Chile published a clinical 
guideline for the management of this type of patients, 
in which the use of prophylactic cholecystectomy in the 
population with gallstone disease, regardless of the presence 
of symptoms is highly recommended (65). In contrast, 
prophylactic cholecystectomy is not recommended in the 
majority of patients with asymptomatic gallstone disease 
except for select groups (66). 
In summary, GBC is a frequent disease in many western 
regions of South America, with a dismal prognosis in the 
majority of patients. There is an urgent need of developing 
high quality cancer registries in these regions, to perform 
basic research and clinical trials, which can contribute to the 
better management of the patients. 
Conclusions
GBC affects more frequently women in many western 
regions of South America. It represents a significant 
challenge to the public health system because this tumor 
type is among the leading causes of death due to cancer 
in these territories. It is likely that genetic, dietary habits 
and environmental factors contribute to the pathogenesis 
of this disease. Some differences in term of RAS, TP53, 
FHIT and p16 genes abnormalities have been found in 
GBC from South America compared to tumors from 
other regions. However, and similarly to other countries, 
extended cholecystectomy, and eventually adjuvant CHT, 
is the standard procedure for the treatment of resectable 
tumors, while the combination of gemcitabine and cisplatin 
is frequently administrated as the first line CHT for the 
treatment of advanced GBC in South America. In contrast 
to other regions, prophylactic cholecystectomy is a common 
practice in many western areas of South America. Due to 
the high incidence and the dismal outcome of the patients 
with GBC comprehensive and high quality cancer registries 
and more translational research should be carried out in 
order to minimize the negative impact that this disease has 
among South Americans. 
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